AXGT - Axovant Gene Therapies Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Axovant Gene Therapies Ltd.

Eleven Times Square
33rd Floor
New York, NY 10036
United States

Full Time Employees57

Key Executives

NameTitlePayExercisedYear Born
Dr. Pavan Cheruvu M.D.CEO & Director510.96kN/A1982
Dr. Gregory M. WeinhoffPrincipal Financial & Accounting Officer544.08kN/A1971
Dr. David T. Hung M.D.Scientific Advisor of Group3.47MN/A1958
Dr. Fraser WrightChief Technology OfficerN/AN/AN/A
Ms. Tricia TruehartHead of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in New York, New York. Axovant Gene Therapies Ltd. operates as a subsidiary of Roivant Sciences Ltd.

Corporate Governance

Axovant Gene Therapies Ltd.’s ISS Governance QualityScore as of April 1, 2019 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 2; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.